All In Biotech

NDA 217569 · Baxter Hlthcare Corp

Vasopressin In Sodium Chloride 0.9%

Vasopressin · Intravenous

Last checked: Nov 19, 2026Latest source record: Feb 21, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

Sep 29, 2023

Approved uses

1

Original approval plus efficacy supplements

Registered trials

331

81 Phase 3, 37 recruiting

FAERS reports

0

0 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 21, 2025.

Vasopressin in Sodium Chloride Injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. Vasopressin in Sodium Chloride Injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. ( 1 )

Mechanism: Vasopressin causes vasoconstriction by binding to V 1 receptors on vascular smooth muscle coupled to the Gq/11-phospholipase C-phosphatidyl-inositol-triphosphate pathway, resulting in the release of intracellular calcium. In addition, vasopressin stimulates antidiuresis via stimulation of V 2 receptors which are coupled to adenyl cyclase.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 29, 2023 Original approval · Type 5 - New Formulation or New Manufacturer LetterLabelReview
2 products under this application
  • VASOPRESSIN IN SODIUM CHLORIDE 0.9% · VASOPRESSIN 20UNITS/100ML (0.2UNITS/ML) · SOLUTION, INTRAVENOUS · Prescription
  • VASOPRESSIN IN SODIUM CHLORIDE 0.9% · VASOPRESSIN 40UNITS/100ML (0.4UNITS/ML) · SOLUTION, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Vasopressin" as an intervention, any sponsor and status, largest first.

All 331 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals

No FAERS reports name this application.

FAERS reports by year

By the date FDA received the report.

No reports.

Recalls

2 FDA enforcement reports for this application.

  • Aug 6, 2026 · Class II · Ongoing

    CGMP Deviations

  • Aug 6, 2026 · Class II · Ongoing

    CGMP Deviations

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,659 on PubMed

Sponsor: Baxter Hlthcare Corp

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.